DiagnosTear Ltd. – Approval to register patent to its TeaRx ™ technology by the United States Patent and Trademark Office (USPTO)

Tel Aviv (October 15, 2019) – BioLight is pleased to announce that its subsidiary, DiagnosTear Ltd. (“DiagnosTear“)[1], that is engaged in research, development and commercialization of a product that is based on DiagnosTear’s TeaRx ™ technology, which is used to diagnose, personalize treatment and monitor dry eye syndrome by examining the composition of the tear film (“Diagnostear Product”  and the “TeaRx ™ technology”), announced that it received an approval to register a patent from the United States Patent and Trademark Office (USPTO)  (the “Patent“).

[1] Holding via XL Vision Sciences Ltd. (wholly owned subsidiary) approx. 89% of the issued and share capital of Diagnostear (approx. 86% fully diluted).


Link to the complete article

Link to Newsroom

Comments are closed.